Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T23:10:11.470Z Has data issue: false hasContentIssue false

Adrenoleukodystrophy

Published online by Cambridge University Press:  18 September 2015

Brian P. O’Neill*
Affiliation:
the Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN (Dr. O’Neill) and the John F. Kennedy Institute and Department of Neurology, The Johns Hopkins Medical Institutions, Baltimore, MD (Dr. Moser)
Hugo W. Moser
Affiliation:
the Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN (Dr. O’Neill) and the John F. Kennedy Institute and Department of Neurology, The Johns Hopkins Medical Institutions, Baltimore, MD (Dr. Moser)
*
Department of Neurology, Mayo Clinic and Foundation, Rochester, MN 55901
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Adrenoleukodystrophy (ALD) is an X-linked degenerative disease characterized by progressive demyelination and adrenal insufficiency. Several phenotypes are described. In post-mortem tissues there is an accumulation of saturated or mono-unsaturated very long chain fattyacids (VLCFA) in the cholesterol ester fraction of adrenal cortex and cerebral white matter. The accumulated fatty acids are unbranched with carbon chain length between 23 and 32 with most containing 25 or 26 carbons. Determination of VLCFA in readily accessible tissues such as skin fibroblasts and plasma allows for reliable detection of patients and carriers.

Information

Type
Subject Review
Copyright
Copyright © Canadian Neurological Sciences Federation 1982